Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FGF-21 as a novel metabolic regulator.
Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB. Kharitonenkov A, et al. Among authors: shanafelt ab. J Clin Invest. 2005 Jun;115(6):1627-35. doi: 10.1172/JCI23606. Epub 2005 May 2. J Clin Invest. 2005. PMID: 15902306 Free PMC article.
FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho.
Kharitonenkov A, Dunbar JD, Bina HA, Bright S, Moyers JS, Zhang C, Ding L, Micanovic R, Mehrbod SF, Knierman MD, Hale JE, Coskun T, Shanafelt AB. Kharitonenkov A, et al. Among authors: shanafelt ab. J Cell Physiol. 2008 Apr;215(1):1-7. doi: 10.1002/jcp.21357. J Cell Physiol. 2008. PMID: 18064602
Enhancing exposure of protein therapeutics.
Beals JM, Shanafelt AB. Beals JM, et al. Among authors: shanafelt ab. Drug Discov Today Technol. 2006 Spring;3(1):87-94. doi: 10.1016/j.ddtec.2006.03.001. Drug Discov Today Technol. 2006. PMID: 24980106
Receptor-based design of cytokine therapeutics.
Shanafelt AB. Shanafelt AB. Curr Pharm Biotechnol. 2003 Feb;4(1):1-20. doi: 10.2174/1389201033378066. Curr Pharm Biotechnol. 2003. PMID: 12570679 Review.
A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo.
Shanafelt AB, Lin Y, Shanafelt MC, Forte CP, Dubois-Stringfellow N, Carter C, Gibbons JA, Cheng SL, Delaria KA, Fleischer R, Greve JM, Gundel R, Harris K, Kelly R, Koh B, Li Y, Lantz L, Mak P, Neyer L, Plym MJ, Roczniak S, Serban D, Thrift J, Tsuchiyama L, Wetzel M, Wong M, Zolotorev A. Shanafelt AB, et al. Among authors: shanafelt mc. Nat Biotechnol. 2000 Nov;18(11):1197-202. doi: 10.1038/81199. Nat Biotechnol. 2000. PMID: 11062441
Therapeutic enhancement of IL-2 through molecular design.
Cassell DJ, Choudhri S, Humphrey R, Martell RE, Reynolds T, Shanafelt AB. Cassell DJ, et al. Among authors: shanafelt ab. Curr Pharm Des. 2002;8(24):2171-83. doi: 10.2174/1381612023393260. Curr Pharm Des. 2002. PMID: 12369861 Review.
27 results